167 related articles for article (PubMed ID: 36505870)
21. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
[TBL] [Abstract][Full Text] [Related]
22. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
Lamb YN
Target Oncol; 2021 Sep; 16(5):687-695. PubMed ID: 34564820
[TBL] [Abstract][Full Text] [Related]
23. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
24. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
Front Oncol; 2021; 11():733276. PubMed ID: 34760695
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
[TBL] [Abstract][Full Text] [Related]
26. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
[TBL] [Abstract][Full Text] [Related]
27. Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report.
Chen CY; Fares CM; Shin DS
J Med Case Rep; 2021 Apr; 15(1):216. PubMed ID: 33892800
[TBL] [Abstract][Full Text] [Related]
28. An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.
Qi Y; Xia X; Shao L; Guo L; Dong Y; Tian J; Xu L; Niu R; Wei S
Front Oncol; 2022; 12():616546. PubMed ID: 35978809
[TBL] [Abstract][Full Text] [Related]
29. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
30. A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study.
Liu B; Liu X; Xing H; Ma H; Lv Z; Zheng Y; Xing W
Front Oncol; 2024; 14():1349172. PubMed ID: 38414743
[TBL] [Abstract][Full Text] [Related]
31. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
32. Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report.
Ren F; Wang Y; Gao Y; Meng X
Front Oncol; 2022; 12():971192. PubMed ID: 36110968
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report.
Zou F; Xie G; Ma JA; Zhou DA; Jiang YI; Zheng JY
Oncol Lett; 2015 May; 9(5):2239-2243. PubMed ID: 26137049
[TBL] [Abstract][Full Text] [Related]
34. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
35. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
Mountzios G
Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
[TBL] [Abstract][Full Text] [Related]
36. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
Doval DC; Desai CJ; Sahoo TP
Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
[TBL] [Abstract][Full Text] [Related]
37. Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients.
Fuchs V; Kian W; Lichtenberg R; Cooper JM; Remilah AA; Levin D; Peled N; Roisman LC
Clin Drug Investig; 2022 Feb; 42(2):185-192. PubMed ID: 35044639
[TBL] [Abstract][Full Text] [Related]
38. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]